Aurinia Pharmaceuticals Initiates Rolling Submission of a New Drug Application to the U.S. Food and Drug Administration for Voclosporin in the Treatment of Lupus Nephritis Mar 16, 2020
Aurinia Launches Resource Kit for People Living With Lupus Nephritis and Partners With National Kidney Foundation on Awareness Initiative Mar 12, 2020
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights Mar 5, 2020
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020 Mar 3, 2020
Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team Feb 25, 2020
Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference Feb 21, 2020
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares Dec 12, 2019
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis Dec 4, 2019
